Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Deal Watch

- PMLiVE

Deal or no deal? Brexit battlelines drawn in Tory leadership bids

Pharma industry warns again on no-deal impact

- PMLiVE

Genfit presses the gas on NASH with combo trials

Latest move in tight race for NASH prize

- PMLiVE

As Europe goes to polls, pharma seeks to keep healthcare, R&D a priority

Eurosceptics want to block greater EU integration

- PMLiVE

No deal or revoke looming as fourth vote on Brexit nears

Voters set to protest via EU elections, no-deal remains possibility

- PMLiVE

Tax credit changes could put a ‘hard brake’ on UK biotech

Anti-fraud measures will hit genuine firms, fears BIA

- PMLiVE

Brexit “having impact on EU drug development”

EMA and UK regulator both affected

- PMLiVE

Brexit clock ticking once again, UK heads for European elections

New deadline gives pharma more time, but no more clarity

- PMLiVE

Gilead’s NASH drug fails again

Drug failed to match results from placebo group

- PMLiVE

Genfit claims FDA breakthrough status for liver disease drug

Elafibranor up for speedy US review

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links